ReviewRheumatology (Oxford, England)2019
Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy.
Review in Rheumatology (Oxford, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 77 citations in OpenAlex.
- Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2020Guideline
- Optimizing management of immune checkpoint inhibitor-induced inflammatory arthritis: A case series and literature review.Experimental and therapeutic medicine · 2026Article
- Article
- Rheumatic immune-related adverse effects of immune checkpoint treatment: a retrospective multicentre study.Scientific reports · 2026Observational
- A case of severe bilateral corneal ulcer associated with sintilimab therapy: case report and literature review.Frontiers in pharmacology · 2026Article
- Use of Apremilast for the Treatment of Immune Checkpoint Inhibitor Psoriasis and Psoriatic Arthritis.Arthritis care & research · 2025Observational
- Review
- Two clinical subgroups of immune checkpoint inhibitor-induced inflammatory arthritis determined by latent class analysis.Seminars in arthritis and rheumatism · 2025Article
- Eosinophilic Fasciitis in a 78-Year-Old Man Following Pembrolizumab Treatment for Bladder Cancer.The American journal of case reports · 2025Article
- Article
- Soluble Co-Inhibitory Immune Checkpoint Molecules Are Increased in Patients With Polymyalgia Rheumatica Without Significant Correlations With Clinical Status: A Case-Control Study.ACR open rheumatology · 2025Article
- Immune checkpoint inhibitors and rheumatoid arthritis: All roads lead to PD-1?Seminars in arthritis and rheumatism · 2025Review
- The clinical characteristics, mechanism and management of immune checkpoint inhibitor-related arthritis.Frontiers in immunology · 2025Review
- Rheumatic adverse events of immune checkpoint inhibitors in cancer immunotherapy.Expert review of clinical immunology · 2024Review
- Rapid onset pembrolizumab-induced inflammatory arthritis diagnosed using musculoskeletal ultrasound.BMJ case reports · 2024Article
- Immune Checkpoint Inhibitors and Scleroderma: Data from the European Pharmacovigilance Database.Drugs - real world outcomes · 2024Article
- Immune Checkpoint Inhibitors and Lupus Erythematosus.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Immune checkpoints in rheumatoid arthritis: progress and promise.Frontiers in immunology · 2023Review
- Mucocutaneous adverse events to immune checkpoint inhibitors.Frontiers in allergy · 2023Review
- Expert Clinical Management of Severe Immune-Related Adverse Events: Results from a Multicenter Survey on Hot Topics for Management.Journal of clinical medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors have advanced the treatment paradigm of various cancers, achieving remarkable survival benefits. However, a myriad of immune-related adverse events (irAE) has been recognized in almost every organ system, presumably because of persistent immune system activation. Rheumatic symptoms such as arthralgia or myalgia are very common. More specific irAE are increasingly being reported. The most frequent ones are inflammatory arthritis, polymyalgia-like syndromes, myositis and sicca manifestations. These rheumatic irAE can develop in ∼5-10% of patients treated with immune checkpoint inhibitors, although true incidence rates cannot be estimated given the lack of prospective cohort studies, and likely underreporting of rheumatic irAE in oncology trials. In this review, we will provide a summary of the epidemiologic data reported for these rheumatic irAE, until more robust prospective longitudinal studies become available to further define the true incidence rate of rheumatic irAE in patients receiving these novel cancer therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.